Cargando…

Barriers and motivators to participation and retention in HIV/HCV cohort studies among people who inject drugs: a community consultation in Iran

BACKGROUND: The lack of robust estimates of HIV/HCV incidence among people who inject drugs (PWID) in Iran calls for well-designed prospective cohort studies. Successful recruitment and follow-up of PWID in cohort studies may require formative assessment of barriers PWID are faced with in participat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirzazadeh, Ali, Hosseini-Hooshyar, Samira, Shahesmaeili, Armita, Bahramnejad, Ali, Barshan, Adibeh, Mousavian, Ghazal, Najafi, Esmail, Sharifi, Hamid, Haghdoost, Ali-Akbar, Briceno, Alya, McFarland, Willi, Page, Kimberly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405425/
https://www.ncbi.nlm.nih.gov/pubmed/32758246
http://dx.doi.org/10.1186/s13011-020-00298-y
_version_ 1783567247189475328
author Mirzazadeh, Ali
Hosseini-Hooshyar, Samira
Shahesmaeili, Armita
Bahramnejad, Ali
Barshan, Adibeh
Mousavian, Ghazal
Najafi, Esmail
Sharifi, Hamid
Haghdoost, Ali-Akbar
Briceno, Alya
McFarland, Willi
Page, Kimberly
author_facet Mirzazadeh, Ali
Hosseini-Hooshyar, Samira
Shahesmaeili, Armita
Bahramnejad, Ali
Barshan, Adibeh
Mousavian, Ghazal
Najafi, Esmail
Sharifi, Hamid
Haghdoost, Ali-Akbar
Briceno, Alya
McFarland, Willi
Page, Kimberly
author_sort Mirzazadeh, Ali
collection PubMed
description BACKGROUND: The lack of robust estimates of HIV/HCV incidence among people who inject drugs (PWID) in Iran calls for well-designed prospective cohort studies. Successful recruitment and follow-up of PWID in cohort studies may require formative assessment of barriers PWID are faced with in participation and retention in cohort studies and factors they think may facilitate their engagement in such studies. Using a focus group discussion (FGD) format, we conducted a consultation with PWID in southeast Iran to recognize those barriers and motivators. METHODS: Using targeted sampling and through snowball referrals, we recruited PWID (aged≥18, injected in last 6 months) from community-based drop-in centers (DICs), homeless shelters, and through outreach efforts to participate in four FGDs (one women-only). Socio-demographic characteristics, injection behaviors and self-reported HCV/HIV testing and diagnosis history were obtained. Then, a semi-structured FGD guide was applied to explore barriers and motivators to participation and retention in cohort studies among study participants. All FGD sessions were recorded and transcribed verbatim, removing any identifying information. The content of FGDs were analyzed by thematic analysis using an inductive approach. RESULTS: In total, 30 individuals (10 women) participated in the study. The median age of participants was 35 (IQR 31–40), with majority (73.3%) reporting injecting drug use within the last month. Only 40.0% reported ever being tested for HCV whereas a larger proportion (63.4%) reported ever being tested for HIV. While the majority were willing to participate in cohort studies, breach of confidentiality, fear of positive test results, perceived required commitment, and marginalization were reported as barriers to participation and retention in such studies. Monetary incentive, the thought of a better life, protection from police interventions and trust between health workers and PWID were addressed as motivators of engagement in cohort studies among PWID. CONCLUSIONS: Strategies to enhance data security and reduce stigma associated with injecting drug use along with involving peer workers in research, providing pre and post-test counselling and education and addressing the needs of more marginalized groups potentially through integrated healthcare programs and housing support are among few approaches that may help address barriers and strengthen the motivators for successful cohort studies among this population.
format Online
Article
Text
id pubmed-7405425
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74054252020-08-07 Barriers and motivators to participation and retention in HIV/HCV cohort studies among people who inject drugs: a community consultation in Iran Mirzazadeh, Ali Hosseini-Hooshyar, Samira Shahesmaeili, Armita Bahramnejad, Ali Barshan, Adibeh Mousavian, Ghazal Najafi, Esmail Sharifi, Hamid Haghdoost, Ali-Akbar Briceno, Alya McFarland, Willi Page, Kimberly Subst Abuse Treat Prev Policy Research BACKGROUND: The lack of robust estimates of HIV/HCV incidence among people who inject drugs (PWID) in Iran calls for well-designed prospective cohort studies. Successful recruitment and follow-up of PWID in cohort studies may require formative assessment of barriers PWID are faced with in participation and retention in cohort studies and factors they think may facilitate their engagement in such studies. Using a focus group discussion (FGD) format, we conducted a consultation with PWID in southeast Iran to recognize those barriers and motivators. METHODS: Using targeted sampling and through snowball referrals, we recruited PWID (aged≥18, injected in last 6 months) from community-based drop-in centers (DICs), homeless shelters, and through outreach efforts to participate in four FGDs (one women-only). Socio-demographic characteristics, injection behaviors and self-reported HCV/HIV testing and diagnosis history were obtained. Then, a semi-structured FGD guide was applied to explore barriers and motivators to participation and retention in cohort studies among study participants. All FGD sessions were recorded and transcribed verbatim, removing any identifying information. The content of FGDs were analyzed by thematic analysis using an inductive approach. RESULTS: In total, 30 individuals (10 women) participated in the study. The median age of participants was 35 (IQR 31–40), with majority (73.3%) reporting injecting drug use within the last month. Only 40.0% reported ever being tested for HCV whereas a larger proportion (63.4%) reported ever being tested for HIV. While the majority were willing to participate in cohort studies, breach of confidentiality, fear of positive test results, perceived required commitment, and marginalization were reported as barriers to participation and retention in such studies. Monetary incentive, the thought of a better life, protection from police interventions and trust between health workers and PWID were addressed as motivators of engagement in cohort studies among PWID. CONCLUSIONS: Strategies to enhance data security and reduce stigma associated with injecting drug use along with involving peer workers in research, providing pre and post-test counselling and education and addressing the needs of more marginalized groups potentially through integrated healthcare programs and housing support are among few approaches that may help address barriers and strengthen the motivators for successful cohort studies among this population. BioMed Central 2020-08-05 /pmc/articles/PMC7405425/ /pubmed/32758246 http://dx.doi.org/10.1186/s13011-020-00298-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Mirzazadeh, Ali
Hosseini-Hooshyar, Samira
Shahesmaeili, Armita
Bahramnejad, Ali
Barshan, Adibeh
Mousavian, Ghazal
Najafi, Esmail
Sharifi, Hamid
Haghdoost, Ali-Akbar
Briceno, Alya
McFarland, Willi
Page, Kimberly
Barriers and motivators to participation and retention in HIV/HCV cohort studies among people who inject drugs: a community consultation in Iran
title Barriers and motivators to participation and retention in HIV/HCV cohort studies among people who inject drugs: a community consultation in Iran
title_full Barriers and motivators to participation and retention in HIV/HCV cohort studies among people who inject drugs: a community consultation in Iran
title_fullStr Barriers and motivators to participation and retention in HIV/HCV cohort studies among people who inject drugs: a community consultation in Iran
title_full_unstemmed Barriers and motivators to participation and retention in HIV/HCV cohort studies among people who inject drugs: a community consultation in Iran
title_short Barriers and motivators to participation and retention in HIV/HCV cohort studies among people who inject drugs: a community consultation in Iran
title_sort barriers and motivators to participation and retention in hiv/hcv cohort studies among people who inject drugs: a community consultation in iran
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405425/
https://www.ncbi.nlm.nih.gov/pubmed/32758246
http://dx.doi.org/10.1186/s13011-020-00298-y
work_keys_str_mv AT mirzazadehali barriersandmotivatorstoparticipationandretentioninhivhcvcohortstudiesamongpeoplewhoinjectdrugsacommunityconsultationiniran
AT hosseinihooshyarsamira barriersandmotivatorstoparticipationandretentioninhivhcvcohortstudiesamongpeoplewhoinjectdrugsacommunityconsultationiniran
AT shahesmaeiliarmita barriersandmotivatorstoparticipationandretentioninhivhcvcohortstudiesamongpeoplewhoinjectdrugsacommunityconsultationiniran
AT bahramnejadali barriersandmotivatorstoparticipationandretentioninhivhcvcohortstudiesamongpeoplewhoinjectdrugsacommunityconsultationiniran
AT barshanadibeh barriersandmotivatorstoparticipationandretentioninhivhcvcohortstudiesamongpeoplewhoinjectdrugsacommunityconsultationiniran
AT mousavianghazal barriersandmotivatorstoparticipationandretentioninhivhcvcohortstudiesamongpeoplewhoinjectdrugsacommunityconsultationiniran
AT najafiesmail barriersandmotivatorstoparticipationandretentioninhivhcvcohortstudiesamongpeoplewhoinjectdrugsacommunityconsultationiniran
AT sharifihamid barriersandmotivatorstoparticipationandretentioninhivhcvcohortstudiesamongpeoplewhoinjectdrugsacommunityconsultationiniran
AT haghdoostaliakbar barriersandmotivatorstoparticipationandretentioninhivhcvcohortstudiesamongpeoplewhoinjectdrugsacommunityconsultationiniran
AT bricenoalya barriersandmotivatorstoparticipationandretentioninhivhcvcohortstudiesamongpeoplewhoinjectdrugsacommunityconsultationiniran
AT mcfarlandwilli barriersandmotivatorstoparticipationandretentioninhivhcvcohortstudiesamongpeoplewhoinjectdrugsacommunityconsultationiniran
AT pagekimberly barriersandmotivatorstoparticipationandretentioninhivhcvcohortstudiesamongpeoplewhoinjectdrugsacommunityconsultationiniran